Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gore

Showing results (71-80 of 138) with videos related to

Pageof 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II studySanjiv S Agarwala, John M Kirkwood, Martin Gore, et al.
Pigment Cell & Melanoma Research|June 11, 2014
The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysisSimon J Furney, Samra Turajlic, Gordon Stamp, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2013
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancerAntonio Gonzalez-Martin, Laurence Gladieff, Bengt Tholander, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2014
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxelNicholas Coupe, Pippa Corrie, Mirela Hategan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2007
Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy TrialHenrik Schmidt, Stefan Suciu, Cornelis J A Punt, et al.
Investigational New Drugs|August 5, 2010
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanomaSimon Pacey, Martin Gore, David Chao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2015
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized TrialRosalind A Eeles, James P Morden, Martin Gore, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2010
Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapyLiz Y Han, Vasilios Karavasilis, Tom van Hagen, et al.
The Journal of Pathology|April 27, 2013
Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanomaSimon J Furney, Samra Turajlic, Gordon Stamp, et al.
Scientific Reports|July 14, 2016
Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patientsAngela George, Daniel Riddell, Sheila Seal, et al.
Pageof 14

Showing results (71-80 of 138) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II studySanjiv S Agarwala, John M Kirkwood, Martin Gore, et al.
Pigment Cell & Melanoma Research|June 11, 2014
The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysisSimon J Furney, Samra Turajlic, Gordon Stamp, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2013
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancerAntonio Gonzalez-Martin, Laurence Gladieff, Bengt Tholander, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2014
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxelNicholas Coupe, Pippa Corrie, Mirela Hategan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2007
Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy TrialHenrik Schmidt, Stefan Suciu, Cornelis J A Punt, et al.
Investigational New Drugs|August 5, 2010
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanomaSimon Pacey, Martin Gore, David Chao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2015
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized TrialRosalind A Eeles, James P Morden, Martin Gore, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2010
Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapyLiz Y Han, Vasilios Karavasilis, Tom van Hagen, et al.
The Journal of Pathology|April 27, 2013
Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanomaSimon J Furney, Samra Turajlic, Gordon Stamp, et al.
Scientific Reports|July 14, 2016
Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patientsAngela George, Daniel Riddell, Sheila Seal, et al.
Pageof 14